☆ 4.4 Letter

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

HAEMATOLOGICA (2022)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 107, Issue 6, Pages 1460-1465

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2021.279560

Keywords

-

Categories

Hematology

Funding

  1. Acerta Pharma LLC
  2. NIH [AI114554, DK119285]
  3. University of Rochester Research Award
  4. Wilmot Cancer Institute
  5. University of Rochester Research Award, Wilmot Cancer Institute
  6. University of Rochester Immunology Training T32 Grant from NIH [AI007285]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.